Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Koh, Christopher; Canini, Laetitia; Dahari, Hare; Zhao, Xiongce; Uprichard, Susan; Haynes-Williams, Vanessa; Winters, Mark; Subramanya, Gitanjali; Cooper, Stewart; Pinto, Peter; Wolff, Erin; Bishop, Rachel; Han, Ma; Cotler, Scott; Kleiner, David; Keskin, Onur; İDİLMAN, RAMAZAN; Yurdaydin, Cihan; Glenn, Jeffrey; Heller, Theo

doi:10.1016/s1473-3099(15)00074-2

Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Haynes-Williams V., ...Daha Fazla

LANCET INFECTIOUS DISEASES, cilt.15, sa.10, ss.1167-1174, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 15 Sayı: 10
Basım Tarihi: 2015
Doi Numarası: 10.1016/s1473-3099(15)00074-2
Dergi Adı: LANCET INFECTIOUS DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1167-1174
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Evet

Özet

Background Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is essential for HDV and inhibition abrogates HDV production in experimental models. In a proof-of-concept study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the prenylation inhibitor lonafarnib in patients with chronic delta hepatitis.'